Research Analysts Issue Forecasts for United Therapeutics Co.’s Q1 2024 Earnings (NASDAQ:UTHR)

United Therapeutics Co. (NASDAQ:UTHR) – Stock analysts at Leerink Partnrs raised their Q1 2024 earnings per share (EPS) estimates for United Therapeutics in a report issued on Tuesday, March 26th. Leerink Partnrs analyst R. Ruiz now anticipates that the biotechnology company will post earnings of $5.90 per share for the quarter, up from their prior forecast of $5.87. Leerink Partnrs currently has a “Outperform” rating on the stock. The consensus estimate for United Therapeutics’ current full-year earnings is $23.32 per share. Leerink Partnrs also issued estimates for United Therapeutics’ Q2 2024 earnings at $6.26 EPS and FY2024 earnings at $25.95 EPS.

UTHR has been the subject of a number of other reports. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Tuesday. SVB Leerink initiated coverage on United Therapeutics in a report on Monday, February 5th. They set an “outperform” rating and a $330.00 price target for the company. Wells Fargo & Company raised their price target on United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a report on Thursday, March 7th. HC Wainwright reiterated a “buy” rating and issued a $300.00 price objective on shares of United Therapeutics in a research report on Thursday, February 22nd. Finally, The Goldman Sachs Group upgraded United Therapeutics from a “sell” rating to a “neutral” rating and increased their price objective for the company from $213.00 to $215.00 in a research report on Monday, February 12th. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $294.40.

United Therapeutics Trading Down 1.9 %

Shares of UTHR opened at $243.27 on Thursday. United Therapeutics has a 1 year low of $204.44 and a 1 year high of $261.54. The company has a current ratio of 4.41, a quick ratio of 4.28 and a debt-to-equity ratio of 0.05. The stock has a 50 day simple moving average of $225.55 and a 200-day simple moving average of $227.39. The stock has a market cap of $11.45 billion, a PE ratio of 12.26 and a beta of 0.52.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.28 by $0.08. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The business had revenue of $614.70 million during the quarter, compared to analysts’ expectations of $575.01 million. During the same period in the prior year, the firm posted $2.67 EPS. United Therapeutics’s quarterly revenue was up 25.1% compared to the same quarter last year.

Insiders Place Their Bets

In other United Therapeutics news, CEO Martine A. Rothblatt sold 15,000 shares of United Therapeutics stock in a transaction dated Tuesday, March 26th. The stock was sold at an average price of $248.33, for a total transaction of $3,724,950.00. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $32,282.90. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other United Therapeutics news, CEO Martine A. Rothblatt sold 15,000 shares of United Therapeutics stock in a transaction dated Tuesday, March 26th. The stock was sold at an average price of $248.33, for a total value of $3,724,950.00. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $32,282.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Christopher Patusky sold 1,680 shares of United Therapeutics stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $224.00, for a total value of $376,320.00. Following the completion of the sale, the director now directly owns 4 shares in the company, valued at approximately $896. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 76,680 shares of company stock worth $17,886,630. Corporate insiders own 12.50% of the company’s stock.

Hedge Funds Weigh In On United Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. PNC Financial Services Group Inc. grew its position in United Therapeutics by 6.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,636 shares of the biotechnology company’s stock worth $580,000 after buying an additional 164 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its stake in United Therapeutics by 540.5% during the fourth quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 23,700 shares of the biotechnology company’s stock worth $5,211,000 after purchasing an additional 20,000 shares during the last quarter. Fisher Asset Management LLC lifted its stake in United Therapeutics by 5.8% during the fourth quarter. Fisher Asset Management LLC now owns 3,828 shares of the biotechnology company’s stock worth $842,000 after purchasing an additional 209 shares during the last quarter. Virtu Financial LLC bought a new stake in United Therapeutics during the fourth quarter worth $1,353,000. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of United Therapeutics by 31.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 32,045 shares of the biotechnology company’s stock valued at $7,048,000 after acquiring an additional 7,704 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.